No adverse affect in clinical outcome using low pre-ablation diagnostic (131)I activity in differentiated thyroid cancer: refuting thyroid stunning effect.
AffiliationDepartment of Clinical Oncology, The Christie NHS Foundation Trust, Wilmslow Rd, Manchester, M20 4BX, England, U K;
MetadataShow full item record
AbstractContext Published studies of thyroid stunning due to pre-ablation (131)I scanning in the treatment of differentiated thyroid cancer (DTC) following thyroidectomy had shown inconsistent clinical impact. Objective To evaluate the clinical outcome in patients who were given a low diagnostic (131)I activity (1.1mCi or 40MBq) 6 days prior to radioiodine ablation (RAI). Design/setting Two cohorts of patients treated in a cancer referral center in 2004-2011. The eligibility criteria were 1) diagnosis of differentiated thyroid carcinoma (DTC); 2) total or near total thyroidectomy; 3) no distant metastasis; 4) received ≥82.4mCi (3050MBq) therapeutic (131)I activity. Patients/Interventions 305 consecutive patients treated in 2004-2008 (group A) had a diagnostic activity 1.1mCi of (131)I prior to RAI. The second cohort treated in 2009-2011(group B) consisted of 237 patients who did not undergo diagnostic (131)I scanning prior to RAI. Main outcome measures The tumor recurrence rate at 3 years and quantitative assessment using diagnostic radioiodine scans (DxWBS) and TSH-stimulated thyroglobulin (Tg) levels at 3-12 months post RAI. Results The 3-year recurrence free survival rate were 96.4% in both groups with 4.3% in group A and 3.4% in group B had tumor recurrence (p=0.91). The ablation success rates measured by DxWBS were 97.6% and 100% and by stimulated Tg were 85.3% and 85.8% in group A and B respectively (p=0.62). Conclusions The use of low diagnostic (131)I activity (1.1mCi) given 6 days prior to RAI was safe and convenient without adversely affecting the long term clinical outcome.
CitationNo adverse affect in clinical outcome using low pre-ablation diagnostic (131)I activity in differentiated thyroid cancer: refuting thyroid stunning effect. 2014:20141405 J Clin Endocrinol Metab
JournalThe Journal of Clinical Endocrinology and Metabolism
- 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
- Authors: Dam HQ, Kim SM, Lin HC, Intenzo CM
- Issue date: 2004 Aug
- Thyroid lobe ablation with radioactive iodine as an alternative to completion thyroidectomy after hemithyroidectomy in patients with follicular thyroid carcinoma: long-term follow-up.
- Authors: Barbesino G, Goldfarb M, Parangi S, Yang J, Ross DS, Daniels GH
- Issue date: 2012 Apr
- Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma.
- Authors: Muratet JP, Daver A, Minier JF, Larra F
- Issue date: 1998 Sep
- Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer.
- Authors: Tresoldi AS, Sburlati LF, Rodari M, Schinkelshoek MS, Perrino M, De Leo S, Montefusco L, Colombo P, Arosio M, Lania AGA, Fugazzola L, Chiti A
- Issue date: 2014 Aug
- The clinical effects of thyroid stunning after diagnostic whole-body scanning with 185 MBq 131I.
- Authors: Lees W, Mansberg R, Roberts J, Towson J, Chua E, Turtle J
- Issue date: 2002 Nov